Cloud-Clone launches 11-plex assay for immune and inflammation research

Cloud-Clone Corp. has introduced an 11-plex multiplex assay kit aimed at labs studying immune and inflammatory pathways, with a 50 μL sample requirement and dual-platform compatibility. The company says the kit is designed to help researchers generate more complete cytokine data from scarce clinical samples while reducing reliance on imported testing systems.

Why it matters: - Immune and inflammation researchers often have too little sample volume to run many separate tests. - The new kit is designed to measure 11 biomarkers in one run, which can reduce sample waste and fragmented datasets. - The assay could help labs studying autoimmune disease, infection, chronic inflammation and tumor microenvironments build a fuller view of immune signaling.

What happened: - Cloud-Clone Corp. launched an 11-plex core immune-inflammatory biomarker panel built on its liquid suspension microarray system and Luminex xMAP technology. - The kit is designed to quantify 11 biomarkers from 50 μL of sample in a single loading run. - The product targets researchers working in immune and inflammation studies worldwide.

The details: - The panel includes anti-inflammatory and immune modulatory markers: IL-10, TGF-β1, IL-4 and IL-13. - It includes pro-inflammatory mediators: IFN-γ, IL-1β, IL-6, IL-17 and TNF-α. - It also includes chemokines: MCP-1 and MIP-1α. - The markers are grouped around Th1/Th2/Th17 balance, inflammatory activation, immune tolerance and tissue repair. - The assay is positioned for use in rheumatoid arthritis, systemic lupus erythematosus, asthma, inflammatory bowel disease and sepsis research. - Cloud-Clone says the assay recovery rate stays within 80% to 120%, with linear correlation coefficients of R² ≥ 0.97. - The company says the kit works on both Luminex xMAP and CBA flow cytometry workflows. - The Luminex platform is designed for high-throughput testing with pg/mL-level sensitivity and a 1,000- to 10,000-fold dynamic range. - The CBA flow cytometry workflow is designed to run on standard laboratory flow cytometers without dedicated equipment. - Cloud-Clone says both platforms use the same antibody materials and quality-control system, allowing direct data comparison. - The company says it can independently develop and mass-produce fluorescence-encoded microspheres and target-specific antibody pairs. - Cloud-Clone says its in-house antibody library contains more than 27,000 clones. - The company says it has more than 7,000 detectable biomarkers and more than 350 pre-validated custom panels. - Cloud-Clone says the product series serves more than 5,000 laboratories worldwide.

Between the lines: - The launch targets two persistent lab pain points: limited specimen volume and incompatible data from different platforms or reagent brands. - Dual-platform compatibility is meant to reduce dependence on imported multiplex kits and equipment lock-in. - The pitch also signals a push toward standardized immune-network profiling instead of single-marker testing.

What's next: - Cloud-Clone plans to expand its biomarker library and validated panel portfolio. - The company also says it will continue improving assay performance and customer technical support. - Global logistics support is in place to speed order fulfillment for labs.

The bottom line: - Cloud-Clone is betting that a smaller sample requirement, broader biomarker coverage and cross-platform compatibility can make multiplex cytokine testing more practical for routine research.